Recro Pharma, Inc. (REPH) Loss Submission Form

Recro Pharma, Inc. The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQCM: REPH) violated federal securities laws.

Recro Pharma, Inc.

On May 24, 2018, Recro revealed that the U.S. Food & Drug Administration (the “FDA”) had declined to approve Recro’s New Drug Application for the non-opioid pain relief treatment IV meloxicam. The FDA stated in its Complete Response Letter that the drug’s analgesic effects did not meet its expectations and raised questions related to certain data included in the NDA. Following this news, Recro stock fell 54.7% to close at $5.63 per share on May 24, 2018.

“Recro Pharma, Inc.”

To receive more information, please fill out the form.

Request More Information

The Law Offices of Vincent Wong do not share your information with others. There is no cost or obligation.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained The Law Offices of Vincent Wong to represent you as a named plaintiff in a shareholder action involving Recro Pharma, Inc..

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Recro Pharma, Inc. shareholders.


The Law Offices of Vincent Wong

Vincent Wong

AGREED: Sign Name Clear